Reporting from the 62nd ASH Annual Meeting, Eleni Gavriilaki comments on studies highlighting the hematologic aspect of the COVID-19 pandemic. She details findings about thrombotic microangiopathy variants independantly associated with critical COVID-19 which may help identify patients who could benefit from targeted therapy. She also presents results about the outcome of patients presenting with hematologic malignancy and COVID-19, and explains how allogenic Sars-Cov-2 specific T cells from recovering individuals have been used to treat high risk patients with COVID-19.
Abstracts:
376: Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients
215: Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
612: Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19